Novo Nordisk asks FDA to ban cheap copies of Wegovy, Ozempic, CNBC reports

Novo Nordisk (NVO) has asked the FDA to ban cheap copies of its weight loss drugs Wegovy and Ozempic, arguing they pose safety risks, CNBC’s Annika Kim Constantino reports. The drugmaker contends the medications are too complex for those manufacturers to make safely. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic and Wegovy, CNBC notes.